Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;34(2):644-653.
doi: 10.1007/s13577-020-00471-2. Epub 2021 Jan 17.

High-resolution melting effectively pre-screens for TP53 mutations before direct sequencing in patients with diffuse glioma

Kiyotaka Saito  1 , Kiyotaka Yokogami  2 , Kazunari Maekawa  3 , Yuichiro Sato  3 , Shinji Yamashita  2 , Fumitaka Matsumoto  2 , Asako Mizuguchi  2 , Hideo Takeshima  2
Affiliations

High-resolution melting effectively pre-screens for TP53 mutations before direct sequencing in patients with diffuse glioma

Kiyotaka Saito et al. Hum Cell. 2021 Mar.

Abstract

TP53 mutations are important molecular markers in diffuse astrocytic tumors and medulloblastomas. We examined the efficacy of a pre-screening method for high-resolution melting (HRM) analysis of TP53 mutation before direct sequencing using samples from patients with diffuse glioma. Surgical samples from 64 diffuse gliomas were classified based on the 2016 World Health Organization (WHO) histopathological grading system and the cIMPACT-NOW (consortium to inform molecular and practical approaches to CNS tumor taxonomy-not official WHO) update. TP53 mutations from exon 5 to exon 8 were assessed by direct sequencing. The results of HRM and p53 immunohistochemistry (IHC) analysis were compared by recording the sensitivity, specificity, and false negative and false positive rates. Direct sequencing detected TP53 mutations in 18 of 64 samples (28.1%): diffuse astrocytoma, IDH-mutant (n = 3); diffuse astrocytoma, IDH-wild type (n = 1); anaplastic astrocytoma, IDH-mutant (n = 3); anaplastic astrocytoma, IDH-wild type (n = 4); and glioblastoma, IDH-wild type (n = 7). A total of 22 mutations was detected in the 18 samples; 4 samples exhibited duplicate missense mutations. Sensitivity and specificity were 0.96 and 0.96, respectively, for HRM analysis; they were 0.89 and 0.52, respectively, for p53 IHC. Overall accuracy was 0.98 for HRM and 0.63 for IHC. HRM analysis is a good pre-screening method for the detection of TP53 mutation before direct sequencing.

Keywords: Diffuse glioma; High-resolution melting; Immunohistochemistry; TP53 mutation; p53.

PubMed Disclaimer

References

    1. Komori T. The 2016 WHO classification of tumours of the central nervous system: the major points of revision. Neurol Med Chir Tokyo. 2017;57(7):301–11. https://doi.org/10.2176/nmc.ra.2017-0010 . - DOI - PubMed - PMC
    1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20. https://doi.org/10.1007/s00401-016-1545-1 . - DOI - PubMed
    1. Von Deimling A, Perry A, Louis D, Ohgaki H, Wiestler O, Cavenee W. WHO classification of tumours of the central nervous system. Lyon: IARC; 2016.
    1. Cambruzzi E. Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation. Childs Nerv Syst. 2018;34(5):809–15. https://doi.org/10.1007/s00381-018-3765-2 . - DOI - PubMed
    1. Murnyak B, Hortobagyi T. Immunohistochemical correlates of TP53 somatic mutations in cancer. Oncotarget. 2016;7(40):64910–20. https://doi.org/10.18632/oncotarget.11912 . - DOI - PubMed - PMC

Supplementary concepts

LinkOut - more resources